CJC-1295 Without DAC is a growth peptides research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
CJC-1295 Without DAC — also referred to as Modified GRF (1-29) or Mod GRF 1-29 — is a synthetic 29-amino acid analogue of endogenous growth hormone-releasing hormone (GHRH). It is derived from the biologically active N-terminal fragment of native GHRH (residues 1–29) with four amino acid substitutions: Ala⁸→Gln, Ala¹⁵→Ala (D-Ala), Ala¹⁸→Gln, and Phe²⁹→Tyr. These modifications extend plasma half-life from the ~7 minutes of native GHRH(1-29) to approximately 30 minutes by blocking DPP-IV cleavage at position 2 and reducing peptidase susceptibility at other sites. Critically, it lacks the Drug Affinity Complex (DAC) lysine modification present in CJC-1295 With DAC, so it does not bind albumin and retains a pulsatile pharmacokinetic profile rather than producing sustained GH elevation.
The compound is widely used in GH secretagogue research as the GHRH component of pulse-mimicking study designs. Its pulsatile kinetics align with the endogenous pattern of hypothalamic GHRH release, making it useful for models where maintaining physiological GH pulsatility is important. In most published preclinical protocols, CJC-1295 Without DAC is co-administered with a GHSR-1a agonist — most commonly ipamorelin — to achieve synergistic GH pulse amplification through independent receptor pathways (GHRHR and GHSR-1a respectively).
PeptidesFromChina.co supplies CJC-1295 Without DAC as lyophilized powder, ≥98% purity by HPLC, confirmed by mass spectrometry. Batch COA is available. Suitable for reconstitution in aqueous research buffers. All product is for laboratory research use only.
| Chemical Class | GHRH Analogue (Growth Hormone Releasing Hormone) |
|---|---|
| Also Known As | Modified GRF (1-29), Mod GRF 1-29, Sermorelin analogue |
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₂O₄₂ |
| Molecular Weight | 3367.9 Da |
| Sequence Length | 29 amino acids |
| Receptor Target | GHRHR (Growth Hormone-Releasing Hormone Receptor) |
| Half-life (research) | ~25–30 min (vs. ~7 min for native GHRH) |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 14 days) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| CJC-1295 Without DAC | 2 mg | 10 vials | ≥98% | In Stock | $48.00 |
| CJC-1295 Without DAC | 5 mg | 10 vials | ≥98% | In Stock | $88.00 |
| CJC-1295 Without DAC | 10 mg | 10 vials | ≥98% | In Stock | $175.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis: Simple COA. Documentation is available for every batch sold.
CJC-1295 Without DAC is the standard GHRH-receptor tool compound in pulsatile GH secretagogue studies. Unlike CJC-1295 With DAC, which produces sustained supraphysiological GH elevation over days, the Without DAC variant generates a discrete GH pulse with ~30-min window of activity — more closely approximating endogenous GHRH burst release from the hypothalamus. This kinetic profile is preferable when investigating somatotroph desensitisation, GH feedback loops, or physiological pulse modelling.
Combining a GHRHR agonist (CJC-1295 Without DAC) with a GHSR-1a agonist (ipamorelin, GHRP-2, or GHRP-6) produces synergistic GH release exceeding the sum of each compound alone. This synergy occurs because GHRHR activation increases cAMP-dependent somatotroph excitability, while GHSR-1a activation triggers intracellular calcium release — two independent upstream pathways converging on GH exocytosis. The ipamorelin + CJC-1295 Without DAC combination is the most studied pairing due to ipamorelin's selectivity profile.
In hypophysectomised and GH-deficient rodent models, CJC-1295 Without DAC restores GH pulsatility and partially reverses GH-deficiency phenotypes including lean mass loss, fat accumulation, and reduced IGF-1 levels. Bone mineral density studies in aged rodent models document modest anabolic effects on trabecular bone with pulsatile GHRH stimulation protocols. These models are used to characterise the downstream somatic effects of GH axis activation without exogenous GH administration.
Sermorelin (GHRH 1–29 native sequence) and CJC-1295 Without DAC are structurally related. The four amino acid modifications in CJC-1295 Without DAC increase metabolic stability while retaining full GHRHR agonism. Comparative studies in rat models show CJC-1295 Without DAC produces a larger and more sustained GH peak than equimolar sermorelin due to resistance to DPP-IV cleavage. This makes CJC-1295 Without DAC the preferred research tool when half-life extension is desirable without the sustained release characteristics of the DAC version.
CJC-1295 With DAC (Drug Affinity Complex) contains a lysine-maleimidoproprionic acid modification that enables covalent binding to serum albumin, extending the half-life to 6–8 days and producing sustained, supraphysiological GH elevation. Without DAC, the half-life is approximately 25–30 minutes, generating a discrete pulsatile GH release. Researchers select the version based on whether the study requires prolonged GH elevation (With DAC) or physiological pulsatile GH patterns (Without DAC).
Modified GRF (1-29) is another name for CJC-1295 Without DAC. Its four amino acid substitutions relative to sermorelin improve DPP-IV resistance and peptidase stability, producing a longer and more reproducible GH peak per dose. In practice, it delivers better dose-response consistency in in vivo models compared to sermorelin, making it the preferred GHRH analogue in most current research protocols.
PeptidesFromChina.co supplies CJC-1295 Without DAC as sterile lyophilized powder in sealed vials. Purity ≥98% by HPLC. Reconstitute with bacteriostatic water or sterile saline. Available in standard research vial sizes with Certificates of Analysis per batch.
Yes. GHRHR-transfected cell lines and primary pituitary cultures are used for in vitro characterisation of CJC-1295 Without DAC. cAMP accumulation assays and GH release assays from primary rat anterior pituitary cells are the standard in vitro formats. The peptide is stable in cell culture conditions over typical assay time windows (1–4 hours).
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.